
San Francisco small businesses struggle to navigate 90-day tariff pause
Some are seeing some immediate shifts, while others are trying to figure out what to do next.
In the wake of Trump's stop-and-go tariff policies, business owners like Edward Lau are confused about what and when to order from Chinese importers as inventory levels dwindle.
"You don't know what to do, honestly. You don't know whether this 90-day (pause) is temporary," he said.
Customers continuously ask the herbal medicine store operator when prices will stabilize. He readily admits that's above his pay grade.
Since March, Lau has raised prices while absorbing other costs to remain competitive with similar stores in San Francisco's Chinatown.
"I would say 10-20% at least for some of the products. But for most of the others, we still are at a price that we paid for before the tariff," said Lau.
Lau remains anxious, even though tariffs are significantly lower than the previous 145% hike. A decision to purchase too little now could hurt his bottom line if tariffs ramp up again later this year.
"Once you sell out, you stock up. The price we are getting is much higher than what we are (currently) selling for," said Lau.
Further up the supply chain from Lau, operators of bonded warehouses, where imported goods can be stored without paying duties until they are removed, have seen immediate changes since the tariff pause.
Francisco Garcia, the founder of Lynx Logistics, says requests to remove goods have started.
Container-tracking software provider Vizion also says U.S. container bookings from China surged nearly 300%, soon after the announcement.
But Garcia says many of the larger companies he works with are still asking for long-term bonded storage.
"The big players, the big forwarders, the big direct shippers, are actually asking for more space because these next 90 days are very uncertain," said Garcia.
Uncertainty for a small player in the supply chain like Lau keeps him twisting in the wind, as he sees the hardship it has created every day.
"I see some of the customers getting so frustrated, saying 'I can't afford it,' " said Lau.
Even his son has asked whether running a small store is worth it.
"He's told me I don't see any future in the United States, even though he was born here. It makes me even more nervous now," said Lau.
What is certain is the anxiety Lau is dealing with at the bottom of the supply chain, in the midst of a global trade war. The U.S. lowered its tariffs on Chinese imports from 145% to 30%, while China reduced its tariffs on U.S. goods from 125% to 10%.
The agreement is set for 90 days, during which both nations will engage in further trade discussions.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
CRISPR Therapeutics (CRSP) Sees 47% Price Increase Over Last Quarter
CRISPR Therapeutics recently announced significant developments in its in vivo cardiovascular disease programs, notably CTX310 and CTX320, which may have contributed to the company's 47% share price increase over the last quarter. The company's inclusion in multiple indices further enhances its market presence, potentially impacting investor interest positively. Meanwhile, CRISPR reported a net loss in its Q1 earnings, although revenue increased year-over-year. Despite a volatile market backdrop, characterized by declining major indices due to weak job reports and tariff concerns, CRISPR's advancements in therapeutic programs and strategic index additions contrasted against broader market movements. We've spotted 1 risk for CRISPR Therapeutics you should be aware of. Uncover the next big thing with financially sound penny stocks that balance risk and reward. Over the past year, CRISPR Therapeutics reported a total shareholder return of 9.74%. While the company's shares outperformed the US Biotechs industry, which returned a decline of 8.4% over the same period, it lagged behind the broader US Market's 17.7% return. The favorable performance relative to its industry can be linked to its strategic advancements in cardiovascular disease programs and inclusion in various Russell indices. The recent developments highlighted in the introduction, particularly the positive updates in CRISPR's cardiovascular programs and index additions, could potentially influence expectations around future revenue and earnings. Analysts forecast strong revenue growth of 57.3% annually, despite the company's forecast to remain unprofitable over the next three years. Meanwhile, with the current share price at $56.09, the market seems to discount the consensus analyst price target of $80.91, reflecting a substantial perceived upside potential in the stock. This price movement suggests that investors might see potential growth opportunities, even as the company navigates its profitability challenges. The valuation report we've compiled suggests that CRISPR Therapeutics' current price could be quite moderate. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
15 minutes ago
- Yahoo
An Amazon seller doing 7 figures says one strategic addition has doubled her profit
Lisa Harrington started selling clothes on eBay before transitioning to Amazon. Her business selling interior cat doors took off after hiring a PPC coach. She emphasizes investing in coaching and networking for long-term business growth. Lisa Harrington's e-commerce career began in the early 2010s when she started selling clothing, purses, and other items in her closet that she didn't need anymore. She used the eBay profit to launch her first Amazon product — dog harnesses — and sold enough to quit her corporate job in 2016. She eventually created and patented interior cat doors, which have become a top-selling Amazon product and bring in seven figures in annual revenue. Harrington, who's been doing e-commerce for more than a decade, can pinpoint one decision that took her business to the next level: hiring a PPC coach. PPC (pay-per-click) refers to Amazon's advertising platform, where sellers can pay to have their products displayed prominently. Many sellers consider ads an essential aspect of succeeding in the competitive e-commerce space. For years, "I had a very low spend on my advertisement," Harrington told Business Insider. Figuring out how to run Amazon ads wasn't how she wanted to spend her time. "I just didn't have much interest in it. I really wanted to focus on branding and product development, but it has such an enormous impact on your profit and loss statement that you really can't ignore it." The idea to hire a coach came from an industry event. "I remember talking to this woman, and she's like, 'I hire a coach for everything I don't know how to do. It is the fastest way to level up,'" recalled Harrington. She took the advice, found a coach to help her specifically with ads, and, "in the time I've worked with her, my profit has doubled," said Harrington. It took her six months to find the right fit. "Coaches are hard to find. But when you do find one, it levels your business up," she said. Over the last couple of years, her PPC coach has become more of a general business coach. They discuss everything from product development to effective employee management. "She's the only person I can talk to about every aspect of my business. She not only has the expertise but has the background information, so I can spitball with her, solve problems, and come up with great ideas," said Harrington. The full-time entrepreneur and mother of two kids doesn't hesitate to outsource when she can. "I try to get a coach for everything because, thankfully, I've gotten to the point where I can pay people to help me," she said. "That, in some cases, tends to be a cheaper way to learn a skill or a cheaper way to get something done." Harrington is also a member of the elite group of seven-figure Amazon sellers called Million Dollar Sellers. Members must complete an interview and application and pay $7,497 a year to join the group, which grants them access to exclusive events and a robust network of top-tier entrepreneurs. She's adamant that investing in yourself "always pays dividends," she said. "The knowledge that you gain, the networks that you gain, the experience shares that you hear, the tips and tricks that you get access to — not only is that short-term helping your business and helping your profit and loss statement, but you're also learning all of those things, so that if everything fell apart tomorrow, you could rebuild it again." Read the original article on Business Insider Sign in to access your portfolio
Yahoo
15 minutes ago
- Yahoo
Cleveland-Cliffs (CLF) Reports Q2 2025 Sales Decline to US$4934 Million
Cleveland-Cliffs recently faced challenges as their second-quarter 2025 earnings revealed sales declined to USD 4,934 million, while registering a net loss of USD 483 million compared to a modest net income last year. Despite these disappointing financial results, Cleveland-Cliffs's share price rose by 15% over the past month. This performance unfolded against the backdrop of a broader market that saw similar gains in July, although markets experienced a downturn due to economic concerns fueled by weak U.S. jobs data and renewed tariff policies. The company's operational struggles might have tempered the overall positive market momentum. We've identified 3 risks with Cleveland-Cliffs (at least 1 which is a bit unpleasant) and understanding the impact should be part of your investment process. Find companies with promising cash flow potential yet trading below their fair value. The recent earnings report highlighting Cleveland-Cliffs' net loss of US$483 million amidst sales of US$4.93 billion presents a challenging landscape for the company. Despite this, shares have climbed 15% in the past month, reflecting broader market trends, though these gains might be vulnerable to ongoing economic uncertainties, such as the U.S. jobs data concerns. Addressing this financial strain is crucial as Cleveland-Cliffs navigates its reliance on U.S. steel tariffs and OEM reshoring, central to its growth narrative. Over a longer five-year period, Cleveland-Cliffs' total shareholder return, encompassing both share price appreciation and dividends, marked an impressive increase of 83.58%. This growth sharply contrasts with the company's recent underperformance against the US Metals and Mining industry over the past year. The industry saw returns of 13.4%, surpassing Cleveland-Cliffs' performance during the same one-year period. Future revenue and earnings projections are aligned with anticipated benefits from reshoring and tariff protections, yet the magnitude of the recent loss highlights potential vulnerabilities. Analysts anticipate the revenue will rise, with margins eventually reaching profitability. However, any shifts in trade policies or market conditions could alter these forecasts. With the current share price at US$10.06, close to the target of US$10.99, the upward movement suggests market confidence, yet analysts see limited upside relative to the target, indicating cautious optimism about hitting expected milestones. According our valuation report, there's an indication that Cleveland-Cliffs' share price might be on the cheaper side. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CLF. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data